<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04457050</url>
  </required_header>
  <id_info>
    <org_study_id>020966</org_study_id>
    <nct_id>NCT04457050</nct_id>
  </id_info>
  <brief_title>Effect of Hepatitis C Clearance on Insulin Resistance</brief_title>
  <official_title>Insulin Resistance and Resistin In Non-Diabetic Patients With Chronic Hepatitis C Before and After Direct-Acting Antiviral Drugs.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic hepatitis C infection has been linked to insulin resistance, which is the essential&#xD;
      component of metabolic syndrome and type 2 diabetes mellitus. Resistin; an adipokine, has&#xD;
      been demonstrated to stimulate the secretion of several inflammatory factors known to play a&#xD;
      role in the induction of insulin resistance. we investigated the changes in insulin&#xD;
      resistance after hepatitis C clearance in the era of direct antivirals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the link between hepatitis C infection and insulin resistance has been established. Insuli&#xD;
      resistance has been linked to poor response to interferon based therapy. recently, direct&#xD;
      acting antiviral drugs are approved for hepatitis C elimination with high potency and safety.&#xD;
      The aim of the study is to: 1. Determine the prevalence of insulin resistance among&#xD;
      non-diabetic patients with chronic HCV infection. 2. Explore the impact of treatment with&#xD;
      DAAs on insulin resistance among chronic HCV infected patients. 3. Investigate the role of&#xD;
      insulin resistance as a potential prognostic factor for the response to DAAs. 4. Explore the&#xD;
      utility of resistin as a potential biomarker IR among HCV infected patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the insulin resistance before and after hepatitis C clearance</measure>
    <time_frame>at baseline and 12 weeks after sustained virologic response</time_frame>
    <description>Assess the change in the value of Homeostatic Model Assessment for Insulin resistance (Homeostatic Model Assessment for Insulin Resistance) after hepatitis C treatment by calculating the HOMA-IR for all patients at baseline and the re-calculation at 12 weeks after viral clearance to clarify the impact of hepatitis C treatment by direct antiviral drugs on insulin sensitivity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of insulin resistance among hepatitis C patients</measure>
    <time_frame>at baseline</time_frame>
    <description>Prevalence of insulin resistance among hepatitis C patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained virologic response</measure>
    <time_frame>at 12 weeks after treatment</time_frame>
    <description>Sustained virologic response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Non-Diabetic Hepatitis C infected patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clinical examination,&#xD;
measurement of weight (Kg), height (meter), and waist circumference (cm).&#xD;
Calculation of the body mass index.&#xD;
Ultrasound abdominal examination.&#xD;
Laboratory Investigations including Complete blood count, Serum aspartate and alanine aminotransferases, serum albumin, serum bilirubin, serum gamma-glutamyl transpeptidase, and international normalization ratio. HCV-RNA quantification before treatment and 12 weeks after the end of therapy.. Serum lipid profile, fasting and post-prandial blood sugar, glycated hemoglobin A1c also included.&#xD;
Treatment of all patients with the available generic direct antivirals in Egypt (sofosbuvir/ledipasvir ± ribavirin or sofosbuvir plus daclatasvir ± ribavirin).&#xD;
Evaluation of insulin resistance using the homeostasis model assessment of insulin resistance before and 12 weeks after end of treatment.&#xD;
measurement of serum levels of resistin before and at 12 weeks after treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir 400 milligram</intervention_name>
    <description>single daily dose of 400 milligrams</description>
    <arm_group_label>Non-Diabetic Hepatitis C infected patients</arm_group_label>
    <other_name>Soflanork 400 milligram</other_name>
    <other_name>Gratisovir 400 milligram</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir 60 milligram</intervention_name>
    <description>single daily dose of 60 milligrams for 12 weeks</description>
    <arm_group_label>Non-Diabetic Hepatitis C infected patients</arm_group_label>
    <other_name>Daklanork 60 milligram</other_name>
    <other_name>Daktavira 60 milligram</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin 400 milligram</intervention_name>
    <description>weight based dose, 1200 mg for weight &gt; 75 kilogram, and 1000 milligram if weight &lt; 75 kilograms for 12 weeks</description>
    <arm_group_label>Non-Diabetic Hepatitis C infected patients</arm_group_label>
    <other_name>Riba 400 milligram</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ledipasvir 90milligram/Sofosbuvir 400 milligram Tab</intervention_name>
    <description>single daily dose for 12 weeks</description>
    <arm_group_label>Non-Diabetic Hepatitis C infected patients</arm_group_label>
    <other_name>HARVONI</other_name>
    <other_name>Soflanork plus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hepatitis C treatment-naïve;&#xD;
&#xD;
          -  Non-diabetic patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Seropositivity for hepatitis B virus infection;&#xD;
&#xD;
          -  Diabetes mellitus;&#xD;
&#xD;
          -  Bbody mass index ≥ 30 Kg/M*2;&#xD;
&#xD;
          -  History of alcohol consumption;&#xD;
&#xD;
          -  Endocrinopathies that may affect the glycemic homeostasis;&#xD;
&#xD;
          -  Other known causes of chronic liver disease; Hepatic decompensation [defined as&#xD;
             history of gastrointestinal bleeding (melena and /or hematemesis), jaundice,&#xD;
             coagulopathy, hepatic encephalopathy, and/or ascites]; bleeding diathesis;&#xD;
&#xD;
          -  Connective tissue diseases;&#xD;
&#xD;
          -  Autoimmune diseases;&#xD;
&#xD;
          -  Cardiac, respiratory or renal disease.&#xD;
&#xD;
          -  Patient receiving immuno-modulatory therapy or drugs that affect the blood glucose&#xD;
             levels such as steroids or beta-blockers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Alexandria</city>
        <zip>21521</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Sameh A. Lashen</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

